GenIP has reported a robust first half of 2025, with cash balances rising to $1,077k from $972,000 at the end of 2024, driven by record new orders and disciplined cost management.
The artificial intelligence analytics services provider secured $488,000 in new orders during the six-month period, including significant contract wins in Asia and Saudi Arabia.
GenIP is focused on helping research organisations accelerate the commercialisation of their technological discoveries.
Since its AIM listing in October 2024, GenIP has received total orders worth $981,000, with an outstanding order book of $813,000 providing revenue visibility for the second half of the year.
The company recognises revenue as services are delivered, which explains the rising order book and cash balance, but fairly steady revenues.
Half-year revenue is expected to reach approximately $128,000, marginally ahead of the previous year’s full-year total of $123,000. The company noted that it expected revenues to pick up in the second half of the year as orders are delivered.
The firm said Invention Evaluator services generated the majority of first-half revenue and orders, whilst its Vortechs division is expected to contribute more significantly in the second half.
“We are extremely encouraged by the strong commercial traction we’ve achieved in such a short period since our IPO,” said Melissa Cruz, CEO of GenIP.
“The size and quality of our order book reflect the value our services bring to clients worldwide. We’re seeing increasing demand for our solutions as institutions seek faster, data-driven ways to unlock the value of their innovations. With a strong balance sheet and a growing pipeline of opportunities, we are well positioned to deliver accelerated growth in the second half of the year and beyond.”